Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.67 |
| ▸ | LIPC | P11150 | 1/20 | 0.67 |
| ▸ | LIPE | Q05469 | 1/20 | 0.67 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ABHD16A | O95870 | 1/20 | 0.46 |
| ▸ | PLK1 | P53350 | 3/20 | 0.45 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GALR3 | O60755 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7041440 | 0.86 | FAAH (0.49) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL7047919 | 0.81 | LPL (1.00) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL6601943 | 0.78 | LPL (0.72) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL7044266 | 0.77 | LPL (0.70) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL2836041 | 0.75 | TRPV1 (0.64) | TRPV1KDM4EPLK1PLK3NPC1 | |
| SCHEMBL6603509 | 0.75 | LPL (0.56) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL6604889 | 0.74 | LPL (0.72) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL12440862 | 0.74 | TRPV1 (0.69) | TRPV1KDM4EPLK1PLK3NPC1 | |
| SCHEMBL6601946 | 0.74 | LPL (0.57) | LPLLIPCLIPEFAAHMGLL | |
| SCHEMBL7388485 | 0.73 | ORAI1 (0.67) | TRPV1KDM4EPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| US-6369088-B2 | ANTIDIABETIC AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-09 | — | — | US | disclosed |
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031772-A1 | Substituted 3-phenyl-5-alkoxy-1,3,4-oxadiazol-2-ones, their preparation and their use as pharmaceuticals | CNR1, PTGER1, CNR2 | LPL 1845/4885LIPC 554/4885LIPE 1909/4885 |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | LPL 4/4885LIPC 7/4885LIPE 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.